FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3090870259> ?p ?o ?g. }

• W3090870259 abstract "Abstract Background Some retrospective and in vitro studies suggest that general anesthetics influence breast cancer recurrence and metastasis. We compared the effects of general anesthetics sevoflurane versus propofol on breast cancer cell survival, proliferation and invasion in vitro. The investigation focused on effects in intracellular Ca 2+ homeostasis as a mechanism for general anesthetic-mediated effects on breast cancer cell survival and metastasis. Methods Estrogen receptor-positive (MCF7) and estrogen receptor-negative (MDA-MB-436) human breast cancer cell lines along with normal breast tissue (MCF10A) were used. Cells were exposed to sevoflurane or propofol at clinically relevant and extreme doses and durations for dose- and time-dependence studies. Cell survival, proliferation and migration following anesthetic exposure were assessed. Intracellular and extracellular Ca 2+ concentrations were modulated using Ca 2+ chelation and a TRPV1 Ca 2+ channel antagonist to examine the role of Ca 2+ in mediating anesthetic effects. Results Sevoflurane affected breast cancer cell survival in dose-, time- and cell type-dependent manners. Sevoflurane, but not propofol, at equipotent and clinically relevant doses (2% vs. 2 μM) for 6 h significantly promoted breast cell survival in all three types of cells. Paradoxically, extreme exposure to sevoflurane (4%, 24 h) decreased survival in all three cell lines. Chelation of cytosolic Ca 2+ dramatically decreased cell survival in both breast cancer lines but not control cells. Inhibition of TRPV1 receptors significantly reduced cell survival in all cell types, an effect that was partially reversed by equipotent sevoflurane but not propofol. Six-hour exposure to sevoflurane or propofol did not affect cell proliferation, metastasis or TRPV1 protein expression in any type of cell. Conclusion Sevoflurane, but not propofol, at clinically relevant concentrations and durations, increased survival of breast cancer cells in vitro but had no effect on cell proliferation, migration or TRPV1 expression. Breast cancer cells require higher cytoplasmic Ca 2+ levels for survival than normal breast tissue. Sevoflurane affects breast cancer cell survival via modulation of intracellular Ca 2+ homeostasis." @default.
• W3090870259 created "2020-10-08" @default.
• W3090870259 creator A5012022141 @default.
• W3090870259 creator A5034419008 @default.
• W3090870259 creator A5037290500 @default.
• W3090870259 creator A5047545152 @default.
• W3090870259 creator A5084547085 @default.
• W3090870259 creator A5084548935 @default.
• W3090870259 date "2020-09-29" @default.
• W3090870259 modified "2023-10-07" @default.
• W3090870259 title "Sevoflurane modulates breast cancer cell survival via modulation of intracellular calcium homeostasis" @default.
• W3090870259 cites W1986540947 @default.
• W3090870259 cites W1989326439 @default.
• W3090870259 cites W1993707929 @default.
• W3090870259 cites W2016408413 @default.
• W3090870259 cites W2017593917 @default.
• W3090870259 cites W2021342621 @default.
• W3090870259 cites W2024866328 @default.
• W3090870259 cites W2056341285 @default.
• W3090870259 cites W2059244111 @default.
• W3090870259 cites W2078836017 @default.
• W3090870259 cites W2083260368 @default.
• W3090870259 cites W2118936308 @default.
• W3090870259 cites W2121544816 @default.
• W3090870259 cites W2139010333 @default.
• W3090870259 cites W2158825577 @default.
• W3090870259 cites W2327822695 @default.
• W3090870259 cites W2625116768 @default.
• W3090870259 cites W2690552997 @default.
• W3090870259 cites W2760465038 @default.
• W3090870259 cites W2885961364 @default.
• W3090870259 cites W2889581714 @default.
• W3090870259 cites W2901812023 @default.
• W3090870259 cites W2910892355 @default.
• W3090870259 cites W2954607948 @default.
• W3090870259 cites W2981214241 @default.
• W3090870259 cites W2996235321 @default.
• W3090870259 cites W3010068913 @default.
• W3090870259 doi "https://doi.org/10.1186/s12871-020-01139-y" @default.
• W3090870259 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7526115" @default.
• W3090870259 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32993507" @default.
• W3090870259 hasPublicationYear "2020" @default.
• W3090870259 type Work @default.
• W3090870259 sameAs 3090870259 @default.
• W3090870259 citedByCount "12" @default.
• W3090870259 countsByYear W30908702592021 @default.
• W3090870259 countsByYear W30908702592022 @default.
• W3090870259 countsByYear W30908702592023 @default.
• W3090870259 crossrefType "journal-article" @default.
• W3090870259 hasAuthorship W3090870259A5012022141 @default.
• W3090870259 hasAuthorship W3090870259A5034419008 @default.
• W3090870259 hasAuthorship W3090870259A5037290500 @default.
• W3090870259 hasAuthorship W3090870259A5047545152 @default.
• W3090870259 hasAuthorship W3090870259A5084547085 @default.
• W3090870259 hasAuthorship W3090870259A5084548935 @default.
• W3090870259 hasBestOaLocation W30908702591 @default.
• W3090870259 hasConcept C121608353 @default.
• W3090870259 hasConcept C126322002 @default.
• W3090870259 hasConcept C134018914 @default.
• W3090870259 hasConcept C2778162923 @default.
• W3090870259 hasConcept C2779013556 @default.
• W3090870259 hasConcept C2781453256 @default.
• W3090870259 hasConcept C42219234 @default.
• W3090870259 hasConcept C502942594 @default.
• W3090870259 hasConcept C530470458 @default.
• W3090870259 hasConcept C71924100 @default.
• W3090870259 hasConcept C84606932 @default.
• W3090870259 hasConcept C96232424 @default.
• W3090870259 hasConcept C98274493 @default.
• W3090870259 hasConceptScore W3090870259C121608353 @default.
• W3090870259 hasConceptScore W3090870259C126322002 @default.
• W3090870259 hasConceptScore W3090870259C134018914 @default.
• W3090870259 hasConceptScore W3090870259C2778162923 @default.
• W3090870259 hasConceptScore W3090870259C2779013556 @default.
• W3090870259 hasConceptScore W3090870259C2781453256 @default.
• W3090870259 hasConceptScore W3090870259C42219234 @default.
• W3090870259 hasConceptScore W3090870259C502942594 @default.
• W3090870259 hasConceptScore W3090870259C530470458 @default.
• W3090870259 hasConceptScore W3090870259C71924100 @default.
• W3090870259 hasConceptScore W3090870259C84606932 @default.
• W3090870259 hasConceptScore W3090870259C96232424 @default.
• W3090870259 hasConceptScore W3090870259C98274493 @default.
• W3090870259 hasFunder F4320337337 @default.
• W3090870259 hasFunder F4320337354 @default.
• W3090870259 hasIssue "1" @default.
• W3090870259 hasLocation W30908702591 @default.
• W3090870259 hasLocation W30908702592 @default.
• W3090870259 hasOpenAccess W3090870259 @default.
• W3090870259 hasPrimaryLocation W30908702591 @default.
• W3090870259 hasRelatedWork W1965298510 @default.
• W3090870259 hasRelatedWork W2068408721 @default.
• W3090870259 hasRelatedWork W2093476509 @default.
• W3090870259 hasRelatedWork W2101821182 @default.
• W3090870259 hasRelatedWork W2150216118 @default.
• W3090870259 hasRelatedWork W2904294837 @default.
• W3090870259 hasRelatedWork W3173207637 @default.
• W3090870259 hasRelatedWork W3206864557 @default.
• W3090870259 hasRelatedWork W4304116770 @default.
• W3090870259 hasRelatedWork W4380354235 @default.
• W3090870259 hasVolume "20" @default.

• next